Vaxcyte (NASDAQ:PCVX) Shares Down 4.5%

Vaxcyte, Inc. (NASDAQ:PCVX)’s share price traded down 4.5% on Friday . The stock traded as low as $19.01 and last traded at $19.01. 1,750 shares traded hands during trading, a decline of 100% from the average session volume of 450,583 shares. The stock had previously closed at $19.91.

Separately, Zacks Investment Research lowered shares of Vaxcyte from a “buy” rating to a “hold” rating and set a $28.00 price target on the stock. in a research report on Thursday, January 6th.

The business’s 50 day moving average price is $22.92 and its two-hundred day moving average price is $23.73.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Wednesday, November 10th. The company reported ($0.51) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.04. As a group, equities analysts predict that Vaxcyte, Inc. will post -1.83 earnings per share for the current year.

In other Vaxcyte news, SVP Paul Sauer sold 6,000 shares of Vaxcyte stock in a transaction that occurred on Wednesday, December 29th. The shares were sold at an average price of $25.00, for a total transaction of $150,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Jeff Fairman sold 4,619 shares of Vaxcyte stock in a transaction that occurred on Thursday, December 16th. The shares were sold at an average price of $22.50, for a total transaction of $103,927.50. The disclosure for this sale can be found here. Insiders sold a total of 56,450 shares of company stock worth $1,317,646 in the last ninety days. 21.70% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Manchester Capital Management LLC purchased a new position in Vaxcyte in the third quarter worth $38,000. Macquarie Group Ltd. acquired a new position in Vaxcyte during the 2nd quarter worth approximately $45,000. Royal Bank of Canada increased its holdings in Vaxcyte by 16.7% during the 2nd quarter. Royal Bank of Canada now owns 2,922 shares of the company’s stock worth $66,000 after purchasing an additional 418 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in Vaxcyte by 32.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,117 shares of the company’s stock worth $70,000 after purchasing an additional 761 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of Vaxcyte by 13.4% in the 2nd quarter. Legal & General Group Plc now owns 4,132 shares of the company’s stock valued at $93,000 after acquiring an additional 489 shares during the last quarter. 81.82% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Company Profile (NASDAQ:PCVX)

Vaxcyte, Inc, a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis.

See Also: What is a support level?

Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.